Effects of PCSK9 inhibitors on HDL cholesterol efflux and serum cholesterol loading capacity in familial hypercholesterolemia subjects: a multi-lipid-center real-world evaluation.
PCSK9 inhibitors
cardiovascular risk
cholesterol efflux capacity
cholesterol loading capacity
familial hypercholesterolemia
Journal
Frontiers in molecular biosciences
ISSN: 2296-889X
Titre abrégé: Front Mol Biosci
Pays: Switzerland
ID NLM: 101653173
Informations de publication
Date de publication:
2022
2022
Historique:
received:
21
04
2022
accepted:
27
06
2022
entrez:
5
8
2022
pubmed:
6
8
2022
medline:
6
8
2022
Statut:
epublish
Résumé
Proprotein convertase subtilisin/kexin type 9 (PCSK9), beyond regulating LDL cholesterol (LDL-c) plasma levels, exerts several pleiotropic effects by modulating lipid metabolism in extrahepatic cells such as macrophages. Macrophage cholesterol homeostasis depends on serum lipoprotein functions, including the HDL capacity to promote cell cholesterol efflux (CEC) and the serum capacity to promote cell cholesterol loading (CLC). The aim of this observational study was to investigate the effect of PCSK9 inhibitors (PCSK9-i) treatment on HDL-CEC and serum CLC in patients with familial hypercholesterolemia (FH). 31 genetically confirmed FH patients were recruited. Blood was collected and serum isolated at baseline and after 6 months of PCSK9-i treatment. HDL-CEC was evaluated through the main pathways with a radioisotopic cell-based assay. Serum CLC was assessed fluorimetrically in human THP-1 monocyte-derived macrophages. After treatment with PCSK9-i, total cholesterol and LDL-c significantly decreased (-41.6%,
Identifiants
pubmed: 35928226
doi: 10.3389/fmolb.2022.925587
pii: 925587
pmc: PMC9343790
doi:
Types de publication
Journal Article
Langues
eng
Pagination
925587Informations de copyright
Copyright © 2022 Palumbo, Giammanco, Purrello, Pavanello, Mombelli, Di Pino, Piro, Cefalù, Calabresi, Averna, Bernini, Zimetti, Adorni and Scicali.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Circulation. 2017 Jun 20;135(25):2494-2504
pubmed: 28450350
Ter Arkh. 2018 Sep 20;90(9):27-30
pubmed: 30701731
FEBS Lett. 2005 Dec 5;579(29):6537-42
pubmed: 16289478
Arthritis Rheumatol. 2015 May;67(5):1155-64
pubmed: 25605003
Eur J Clin Invest. 2022 Jul;52(7):e13766
pubmed: 35294778
J Lipid Res. 2017 Jun;58(6):1238-1246
pubmed: 28420704
Clin Pharmacokinet. 2018 Jul;57(7):769-779
pubmed: 29353350
Biomolecules. 2021 Dec 24;12(1):
pubmed: 35053174
J Lipid Res. 2005 Oct;46(10):2246-53
pubmed: 16061948
Expert Opin Pharmacother. 2020 Feb;21(3):353-363
pubmed: 31893957
Expert Opin Biol Ther. 2020 Jan;20(1):35-47
pubmed: 31593483
Arterioscler Thromb Vasc Biol. 2014 Jan;34(1):17-25
pubmed: 24202308
Atherosclerosis. 2021 Apr;323:44-53
pubmed: 33836456
Vascul Pharmacol. 2020 Dec;135:106804
pubmed: 32987194
Biomed Res Int. 2021 Oct 31;2021:8032978
pubmed: 34754882
J Lipid Res. 2012 May;53(5):984-989
pubmed: 22414482
Nat Rev Cardiol. 2021 Oct;18(10):712-723
pubmed: 33833449
J Lipid Res. 2006 Mar;47(3):605-13
pubmed: 16327021
Acta Diabetol. 2021 Jul;58(7):949-957
pubmed: 33745063
Arterioscler Thromb Vasc Biol. 2016 Jan;36(1):181-8
pubmed: 26543100
Lancet Diabetes Endocrinol. 2015 Jul;3(7):507-13
pubmed: 26025389
N Engl J Med. 2014 Dec 18;371(25):2383-93
pubmed: 25404125
JAMA Cardiol. 2019 Jul 1;4(7):613-619
pubmed: 31116355
BMC Cardiovasc Disord. 2021 Jan 7;21(1):19
pubmed: 33413096
J Atheroscler Thromb. 2020 Sep 1;27(9):909-918
pubmed: 32713931
Ann Rheum Dis. 2014 Mar;73(3):609-15
pubmed: 23562986
Circulation. 2021 Jun 8;143(23):2293-2309
pubmed: 34097448
J Clin Med. 2020 Jul 08;9(7):
pubmed: 32650513
Circulation. 2019 Mar 19;139(12):1483-1492
pubmed: 30586750
Circulation. 2020 Feb 11;141(6):444-453
pubmed: 31941372
Clin Chim Acta. 2013 Sep 23;424:245-52
pubmed: 23782937
Cardiovasc Res. 2021 Jul 27;117(9):2054-2068
pubmed: 32991689
N Engl J Med. 2015 May 7;372(19):1870-1
pubmed: 25946300
N Engl J Med. 2017 May 4;376(18):1713-1722
pubmed: 28304224
Biomed Pharmacother. 2022 Jan;145:112460
pubmed: 34864314
J Mol Med (Berl). 2017 Nov;95(11):1153-1165
pubmed: 28785870
J Clin Endocrinol Metab. 2019 Aug 1;104(8):3097-3107
pubmed: 30835274
Front Aging Neurosci. 2019 May 22;11:120
pubmed: 31178716
J Lipid Res. 2009 Feb;50(2):275-84
pubmed: 18827283
J Lipid Res. 2017 Oct;58(10):2051-2060
pubmed: 28830907
Cells. 2021 Mar 05;10(3):
pubmed: 33807918
Rev Physiol Biochem Pharmacol. 2020;177:25-52
pubmed: 32691159
Curr Opin Lipidol. 2012 Jun;23(3):182-189
pubmed: 22488423
Transfus Apher Sci. 2018 Feb;57(1):91-96
pubmed: 29398508
Atheroscler Suppl. 2017 Oct;29:11-16
pubmed: 28965615
J Clin Lipidol. 2018 Sep - Oct;12(5):1086-1094
pubmed: 30314802
Atherosclerosis. 2017 Jan;256:1-6
pubmed: 27940374
Eur Heart J. 2020 Jan 1;41(1):111-188
pubmed: 31504418
Biosci Rep. 2019 Apr 2;39(4):
pubmed: 30867253
Lancet. 2012 Jul 7;380(9836):29-36
pubmed: 22633824
Front Cardiovasc Med. 2021 Dec 13;8:774418
pubmed: 34966797
J Clin Lipidol. 2013 Mar-Apr;7(2):109-16
pubmed: 23415429